Intercellular adhesion molecule-1 gene polymorphism in Iranian patients with multiple sclerosis
S A R Mousavi1, A R Nikseresht, N Arandi
1Department of Neurology, Namazee Hospital, Shiraz, Iran.
European Journal of Neurology
|September 18, 2007
Summary
Intercellular adhesion molecule-1 (ICAM-1) gene variations do not appear to increase the risk of developing multiple sclerosis in the Iranian population. Further research is needed to clarify the role of ICAM-1 gene polymorphisms in multiple sclerosis pathogenesis.
Area of Science:
- Neuroimmunology
- Genetics
- Molecular Biology
Background:
- Intercellular adhesion molecule-1 (ICAM-1) is crucial for leukocyte activation and migration.
- ICAM-1 is expressed on central nervous system (CNS) endothelial cells in multiple sclerosis (MS) patients.
Purpose of the Study:
- To investigate the association between ICAM-1 gene polymorphisms and the risk of developing multiple sclerosis (MS).
- To analyze ICAM-1 gene polymorphisms at codons 241 and 469 in an Iranian population.
Main Methods:
- Case-control study involving 157 MS patients and 156 healthy controls from Iran.
- Genotyping of ICAM-1 gene polymorphisms at codons 241 (exon 4) and 469 (exon 6).
- Analysis of allele and genotype distributions between patient and control groups.
Main Results:
- No significant differences were observed in the G/R241 and K/E469 allele or genotype distributions between MS patients and controls.
- The study found no correlation between the examined ICAM-1 gene polymorphisms and MS susceptibility in this population.
Conclusions:
- The specific ICAM-1 gene polymorphisms studied do not appear to be risk factors for multiple sclerosis in the Iranian population.
- The role of ICAM-1 gene polymorphisms in the pathogenesis of multiple sclerosis remains controversial and requires further investigation.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:31Immunoglobulin-like Cell Adhesion Molecules
Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:22iPS Cell Differentiation
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.